Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells

Man-Yuan Li,Jiao Zhang,Xiao Lu,Dong Zhou,Xu-Feng Deng,Quan-Xing Liu,Ji-Gang Dai,Hong Zheng
DOI: https://doi.org/10.1007/s00280-023-04589-6
2023-09-25
Cancer Chemotherapy and Pharmacology
Abstract:LUAD (Lung adenocarcinoma), the most common subtype of lung carcinoma and one of the highest incidences and mortality cancers in the world remains still a substantial treatment challenge. Ivermectin, an avermectin derivative, has been traditionally used as an antiparasitic agent in human and veterinary medicine practice during the last few decades. Though ivermectin has been shown to be effective against a variety of cancers, however, there is few available data reporting the antitumor effects of ivermectin in LUAD.
oncology,pharmacology & pharmacy
What problem does this paper attempt to address?